Swedish Orphan Biovitrum (OTCMKTS:BIOVF) Sets New 52-Week High – Still a Buy?

Shares of Swedish Orphan Biovitrum (OTCMKTS:BIOVF) hit a new 52-week high on Friday . The company traded as high as $48.00 and last traded at $48.00, with a volume of 100 shares changing hands. The stock had previously closed at $48.00.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on the stock. HC Wainwright assumed coverage on shares of Swedish Orphan Biovitrum in a research note on Wednesday, May 6th. They issued a “buy” rating on the stock. BNP Paribas Exane upgraded Swedish Orphan Biovitrum to an “outperform” rating in a report on Tuesday, February 10th. Zacks Research upgraded Swedish Orphan Biovitrum to a “hold” rating in a research note on Thursday, May 7th. Barclays reiterated an “overweight” rating on shares of Swedish Orphan Biovitrum in a research note on Tuesday, February 24th. Finally, Danske downgraded Swedish Orphan Biovitrum to a “hold” rating in a report on Thursday, February 19th. Four investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy”.

Swedish Orphan Biovitrum Stock Performance

The company has a current ratio of 0.70, a quick ratio of 0.47 and a debt-to-equity ratio of 0.19. The business’s 50-day simple moving average is $43.76 and its two-hundred day simple moving average is $39.33. The company has a market capitalization of $17.09 billion, a PE ratio of 160.00 and a beta of 0.36.

Swedish Orphan Biovitrum (OTCMKTS:BIOVF) last released its quarterly earnings results on Tuesday, April 28th. The company reported $0.45 EPS for the quarter, topping the consensus estimate of $0.38 by $0.07. The business had revenue of $755.76 million for the quarter, compared to analysts’ expectations of $749.76 million. Swedish Orphan Biovitrum had a return on equity of 16.66% and a net margin of 3.37%. On average, analysts predict that Swedish Orphan Biovitrum will post 2.22 earnings per share for the current year.

About Swedish Orphan Biovitrum

Swedish Orphan Biovitrum AB (publ), commonly known as Sobi, is a Stockholm?based biopharmaceutical company specializing in the development, manufacturing and commercialization of treatments for rare diseases. Formed in 2010 through the merger of Swedish Orphan International AB (established 1985) and Biovitrum AB, the company focuses on high?value therapies in hematology, immunology, oncology and genetic/metabolic disorders. Sobi’s strategy centers on building a global specialty care portfolio by in?licensing, acquiring and internally developing innovative products aimed at small patient populations with significant unmet needs.

The company’s marketed portfolio includes recombinant clotting factor therapies such as Elocta (rFVIIIFc) and Alprolix (rFIXFc) for hemophilia A and B, respectively; Ruconest, a recombinant human C1 esterase inhibitor for hereditary angioedema; and Kineret (anakinra) for certain auto?inflammatory conditions.